Design and build of a new Antibody Drug Conjugate (ADC) manufacturing facility in Grangemouth, Scotland.
The new three-storey facility comprises production areas, offices and Quality Control laboratory accommodation.
- FLEXI POD® solution, a hybrid offering a traditional shell and core and offsite manufactured fit-out.
- FLEXI POD® significantly reduced plant and distribution space and internal layout is riser free
- The internal fit-out includes 14 PODs and 210 PAMs.
- Piramal’s first zero carbon emission facility.
Piramal is a world-leading, multi-product facility for clinical and commercial manufacturing of ADCs and other bio-conjugates. ADCs are currently used in targeted cancer treatment but have a wider potential for further applications.
Piramal requested a fast-track solution to increase their manufacturing capabilities quickly. The new three-storey facility comprises production areas, offices and Quality Control laboratory accommodation.
Merit Health was awarded the project in January 2022. We were able to deliver the project 2.5 years faster than traditional design and build. Works on site and in the factory began in February 2022.
The demand for the Piramal product is sufficiently high, as such, the team turned to Merit for its use of a standard platform design which has been previously licensed by the MHRA and CGT Catapult and CPI.
Using the Merit FLEXI POD platform design Version 4a, the design process was completed in 43 weeks from design concept to completion/delivery of the PODs and PAMs to the Piramal facility.
Merit was able to undertake the site works in conjunction with the production of the internal fit-out PAMs and PODs in the Merit factories.